期刊文献+

贝伐珠单抗治疗结直肠癌的用药观察及护理

原文传递
导出
摘要 目的利用贝伐珠单抗靶向治疗技术治疗结直肠癌患者18例,探讨其临床疗效和护理措施。方法选取2012年5月至2013年5月我科收治的结直肠癌患者18例,以贝伐珠单抗靶向治疗,观察其临床疗效和毒副作用,总结用药注意事项和护理体会。结果18例患者中CR0例,PR5例,SD8例,PD5例,有效率27.78%,控制率72.22%;18例患者中,以1—2级毒副作用为主,3~4级毒副作用仅恶心呕吐、食欲减退等消化系统发生率超过20%,其余均在20%以下,无便秘、腹泻、肾功能损害等严重损害,无动静脉栓塞、肠穿孔及出血等。结论贝伐珠单抗治疗结直肠癌,严格按照说明书用药,密切观察不良反应,做好副作用的控制和处理,配合精心护理,可以减轻毒副作用及提高疗效。
作者 胡春仪
出处 《国际护理学杂志》 2013年第12期2909-2911,共3页 international journal of nursing
  • 相关文献

参考文献7

二级参考文献41

  • 1罗荣城,尤长宣.肿瘤生物治疗新进展[J].中国新药杂志,2005,14(2):143-146. 被引量:18
  • 2裘雁冰,陆益,吴洪斌,凌云华.贝伐单抗及其联用化疗方案的不良反应[J].药物不良反应杂志,2006,8(6):431-433. 被引量:27
  • 3Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [ J ]. Ann Oncol, 2008, 19 (9) : 1523-1529.
  • 4Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumors [ J ]. Cancer Control, 2007, 14 (3) : 295-304.
  • 5Thome S, Hobday T, Hillman D, et al. Translational correlates, including outcome for patients with ER-/PR-/HER2-( triple negative (TNeg)) disease from N0234, a phase Ⅱ trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC) [ EB/OL]. ( 2007 ) [ 2009-04-21 ]. http://meeting, ascopubs, org/ cgi/ content/ abstract/ 25 /18_suppl/1071.
  • 6Munoz A, Salut A, Pericay C, et al. Phase Ⅱ trial of capecit- abine, oxaliplatin plus bevacizumab followed by bevacizumab plus erlotinib : XELOBER trial [ EB/OL ]. ( 2008 ) [ 2009-04-21 ]. http://meeting, ascopubs, org/cgi/content/abstract/26/15 _suppl./ 15078.9 maxtoshow = & HITS = 20 & hits = 20 & RESULTFOR- MAT = & fulhext =c. pericay & searchid = I&FIRSTINDEX =0 & resourcetype = HWCIT.
  • 7Von Minckwitz G, Zielinski C, Maartense E, et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment [ EB/OL]. (2008) [ 2009-04-21 ]. http://meeting, ascopubs. org/cgi/content/abstract/26/15 _suppl/1025.
  • 8Cancello G, Montagna E, D'Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer [ J]. Breast Cancer Rcs, 2005, 10 (4) : R60.
  • 9Cunningham D, Humbler Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004, 351 (4): 337- 345.
  • 10Milani M, Harris AL. Targeting tumour hypoxia in breast cancer [J]. Eur J Cancer, 2008, 44( 18): 2766-2773.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部